|
|
|
Basic information
| Name |
Nakajima Kosei |
| Belonging department |
|
| Occupation name |
|
| researchmap researcher code |
B000224207 |
| researchmap agency |
Okayama University of Science |
Teacher Basic Information
Academic Society and Social Activity |
 |
Teacher Activity Information
- 2020/10/Molecular Profiling of Bone Remodeling Occurring in Musculoskeletal Tumors/Nakajima K, Kidani T, Miura H/Journal of Orthopaedic Research (First Author, impact factor 3.494)
- 2021/03/Galectin-3: an immune checkpoint target for musculoskeletal tumor patients/Nakajima K, Balan V, Raz A/Cancer and Metastasis Reviews (First Author, Impact factor 9.264)
- 2020/07/Autocrine Motility Factor and its Receptor Expression in Musculoskeletal Tumors/Nakajima K, Raz A/Journal of Bone Oncology (First author, impact factor 4.072)
- 2017/Cancer Self-Defense: An Immune Stealth./Cancer Research (First Author, impact factor 9.130)
- 2016/03/Galectin-3 cleavage alters bone remodeling: Different outcomes in breast and prostate cancer skeletal metastasis. /Cancer Research (First Author, impact factor 9.122)
- 2020/09/T cell Infiltration Profile in Musculoskeletal Tumors/Nakajima K, Raz A/Journal of Orthopaedic Research (First Author, impact factor 3.494)
- 2022/03/Neoadjuvant chemo/radiotherapy alters the collagen architecture of tumor microenvironment via Ephrin-A5 pathway./Nakajima K, Ino Y, Naito C, Nara S, Shimasaki M, Iwasaki T, Doi N, Esaki M, Kishi Y, Shimada K, and Hiraoka N/British Journal of Cancer (First Author, Impact factor 7.64)
- 2021/01/Normalization of tumor osteo-immunological microenvironment in bone tumors/Nakajima K.
- 2016/Galectin-3 in Bone Tumor Microenvironment: A Beacon for Individual Skeletal Metastasis Management. /Nakajima K, Kho DH, Yanagawa T, Zimel M, Heath E, Hogan V, Raz A./Cancer and Metastasis Reviews (First Author, impact factor 6.081)
- 2020/10/IAP inhibitor, Embelin increases VCAM-1 levels on endothelium, producing lymphocytic infiltration and antitumor immunity/Nakajima K, Ino Y, Yamazaki-Itoh R, Naito C, Shimasaki M, Takahashi M, Esaki M, Nara S, Kishi Y, Shimada K, Hiraoka N./Oncoimmunology (First author, impact factor 8.110)
- 2020/06/Amplification of Autocrine Motility Factor and its Receptor in Multiple Myeloma and other Musculoskeletal Tumors/Nakajima K, Raz A/Journal of Bone Oncology (First author, impact factor 4.072)
- 2014/11/Galectin-3 inhibits osteoblast differentiation through Notch signaling. /Neoplasia (First Author, impact factor 4.252)
- 2020/Drug screening with a novel tumor-derived cell line identified alternative therapeutic options for patients with atypical teratoid/rhabdoid tumor/Nakano Y, Takadera M, Miyazaki M, Qiao Z, Nakajima K, Noguchi R, R Oyama R, Kimura Y, Okuhiro Y, Yamasaki K, Kunihiro N, Fukushima H, Inoue T, Hara J, Ozawa T, Kondo T, Ichimura K/Human Cell (impact factor 3.463)
- 2020/Pharmacological Profiling of Suppressive Drugs to Musculoskeletal Tumors/Nakajima K./Sarcoma Rseaseach International (First Author, Impact factor 1.2)
- 2016/10/Positive association between Galectin-3 and PSA levels in prostate cancer patients: A prospective clinical study-I./Oncotarget (First author, impact factor 5.168)
- 2016/10/The influence of PSA autoantibodies in prostate cancer patients: A prospective clinical study-II. /Oncotarget (First Author, impact factor 5.168)
- 2015/08/Extracellular galectin-3 programs multidrug resistance through Na+/K+-ATPase and P-glycoprotein signaling./Oncotarget (impact factor 5.008)
- 2015/03/Gp78, an E3 ubiquitinligase acts as a gatekeeper suppressing nonalcoholic steatohepatitis (NASH) and liver cancer./PLoS One (impact factor 3.057)
- 2014/10/Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinomacells./Oncotarget (impact factor 6.359)
- 2014/Why anti-Bcl-2 clinical trials fail: a solution./Harazono Y, Nakajima K, Raz A.
- 2012/12/Hyperthermia reduces migration of osteosarco ma by suppression of au tocrine motility factor. /Oncology Reports (First Autnor, impact factor 2.297)
- 2010/06/Expression of CD44v6 as matrix-associated ectodomain in bone development./Journal of Veterinary Medical Science (First Author, impact factor 0.722)
- ESTABLISHMENT AND CHARACTERIZATION OF CELL LINE OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA/TAKAI Y, OYAMA R, KITO F, SAKUMOTO M, SHIOZAWA K, QIAO Z, NAKAJIMA K, TAKAHASHI M, YOSHIDA A, SETSU N, KOBAYASHI E, KAWAI A, KONDO T/Tiss Cult Res Commun
- Human asymptomatic/smoldering Waldenstrom’s macroglobulinemia-like condition in a dog/Nakajima K, Koitabashi Y, Shirakawa M, Okubo F/Journal of Japan Veterinary Cancer Society (First Author）
- Reduction of intrapancreatic neural density in cancer tissue predicts poorer outcome in pancreatic ductal carcinoma./Iwasaki T, Hiraoka N, Ino Y, Nakajima K, Kishi Y, Nara S, Esaki M, Shimada K, Katai H./Cancer Science (impact factor 4.751)
- 2022/03/18 関節腫瘍の診断と治療～比較整形外科学の大光～ 中嶋幸生 第103回 日本獣医麻酔外科学会 教育講演（整形外科学）
- 2021/07/15/Immune landscape of T cell infiltration profile in musculoskeletal tumors./Nakajima K, Raz A
- 2021/07/15/Molecular landscape of autocrine motility factor and its receptor expression in musculoskeletal tumors/Nakajima K, Raz A
- 2021/04/22/IAP inhibitor, Embelin increases VCAM-1 levels on endothelium, producing lymphocytic infiltration and antitumor immunity/Nakajima K, Ino Y, Yamazaki-Itoh R, Naito C, Shimasaki M, Takahashi M, Esaki M, Nara S, Kishi Y, Shimada K, Hiraoka K
- 2021/Autocrine Motility Factor and its Receptor Expression in Musculoskeletal Tumors/Nakajima K, Raz A./Orthopedic Research Society Annual Meeting
- 2021/Molecular profiling of Bone Remodelling Occuring Musculoskeletal Tumors/Kosei Nakjima, Teruki Tidani, Hiromasa Miura/Orthopedic Research Society Annual Meeting
- 2020/Amplification of Autocrine Motility Factor and its Receptor in Multiple Myeloma and other Musculoskeletal Tumors. /Nakajima K, Raz A/第79回日本癌学会学術総会
- 2020/Immune landscape of neoadjuvant/preoperative chemoradiotherapy in refractory cancer/Nakajima et al/American Society of Clinical Oncology（ASCO) meeting
- 2020/Pharmacological profiling of suppressive drugs to musculoskeletal tumors/Nakajima K/European Orthopaedic Research Society 28th Annual Meeting
- 2020/T cell infiltration profile in musculoskeletal tumors/Nakajima K, Raz A/European Orthopaedic Research Society 28th Annual Meeting
- 2020 こんなにかんたん！より良い小動物臨床のための医療統計学 中嶋幸生 第99回日本獣医麻酔外科学会
- 2020 やってみよう！より良い小動物臨床のための医療統計学 中嶋幸生 第99回日本獣医麻酔外科学会
- 2020 悪性骨軟部腫瘍1384症例におけるGalectin-3(LGALS3)の発現プロファイリング 中嶋幸生 木谷彰岐 Avraham Raz 第93回日本整形外科学会 学術総会
- 2019/09/26/Neoadjuvant therapy alters the collagen architecture via Ephrin-A5/Nakajima K, Ino Y, Naito C, Nara S, Shimasaki M, Iwasaki T, Doi N, Esaki M, Kishi Y, Shimada K, and Hiraoka N
- 2019/Neoadjuvant therapy alters collagen architecture of refractory cancer/Nakajima k, Ino Y, Hiraoka N/American Association for Cancer Research (AACR) Annual Meeting 2019
- 2019 明日からの臨床に役に立つ！ミクロな目で見る整形外科学 第98回日本獣医麻酔外科学会
- 2018 人医学研鑽のすすめ～臨床獣医師が人医学を勉強するために知っておきたいこと～ 中嶋幸生 第97回日本獣医麻酔外科学会
- 2017/Characterization of tumor endothelial cells: Approach to enhance immune cell infiltration for immunotherapy/Nakajima et al/American Association for Cancer Research (AACR) International Cancer Immunotherapy Conference
- 2016/Cancer Autoantibodies are functional or non-functinnal? : A Potential cause and new categorization of cancer-derived factors/Nakajima et al/2016 Michigan Cancer Consortium annual meeting
- 2016/Cancer-secreted Galectin-3 inhibits osteoblast differentiation in bone metastatic niche./2016 Michigan Cancer Consortium annual meeting
- 2016/Galectin-3 as prostate cancer biomarker: A prospective clinical study-I/Nakajima et al/2016 Michigan Cancer Consortium annual meeting
- 2016/Galectin-3 cleavage alters bone remodeling: Different outcomes in breast and prostate cancer skeletal metastasis/Kosei Nakajima et al/MusculoSkeletal Tumor Society Meeting
- 2016/How skeletal tumors destroy bone? : Comparison of bone tumor microenvironments and A solution/Kosei Nakajima et al/Michigan Cancer Consortium Annual Meeting
- 2016/Targeting Galectin-3 suppresses osteolytic remodeling in bone tumor microenvironment./Nakajima et al/2016 Michigan Cancer Consortium annual meeting
- 2016/The influence of PSA autoantibodies in prostate cancer/Nakajima et al/43rd International Society of Oncology and Biomarkers
- 2016/The influence of PSA autoantibodies in prostate cancer patients: A prospective clinical study-II/Nakajima et al/2016 Michigan Cancer Consortium annual meeting
- 2013 腫瘍外科における分子生物学の基礎 中嶋幸生 第85回獣医麻酔外科学会
- 2012 ハイパーサーミアおよびheat shock protein 阻害剤による骨肉腫細胞株におけるautocrine motily factor 発現への影響 第45回日本整形外科学会 骨軟部腫瘍学術集会
- 2012 ハイパーサーミアによる骨肉腫に対するAutocrine Motiliy Factor 発現抑制 中嶋幸生 柳川天志 骨軟部腫瘍の基礎を語る会 2012
- 2012 断脚術の今と将来 中嶋幸生 第84回獣医麻酔外科学会
- 2010 ワルデンシュトレーム・マクログロブリン血症の1例、および17症例の回顧的考察 (1970-2010). 中嶋幸生 小板橋禎見 白川美穂 大久保文葉 第3回日本獣医がん学会
Competitive research funds |
|
Other Research Achivements |
|
Educational Improvement Achievement |
|
On-campus Conference Management |
|
Off-campus Conference Management |
|
|
